Condition
Advanced Cutaneous Melanoma
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Terminated1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07155317Phase 2Recruiting
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
NCT05050006Phase 2TerminatedPrimary
ITIL-168 in Advanced Melanoma
NCT01511913CompletedPrimary
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Showing all 3 trials